Navigation Links
China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit
Date:9/4/2009

SHANGHAI, Sep. 4 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics," "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that the Company's management team will attend the Susquehanna International Group of Companies ("SIG") 3rd Annual Beijing Management Summit.

The SIG 3rd Annual Beijing Management Summit a two-day conference that brings together executives from public and private companies based in China and other emerging Asian economies. The event will showcase leading companies in the Chinese Consumer, Health Care, Internet, and Technology sectors, as well as companies in the IT Services/Outsourcing and Financial Technologies sectors. The event format will consist of one-on-one meetings and company presentations.

The date and location of China-Biotics' one-to-one meetings at the SIG 3rd Annual Beijing Management Summit are as follows:

    Date:         September 16 and September 17, 2009
    Management:   Mr. Lewis Fan, Chief Financial Officer
    Venue:        The Grand Hyatt Beijing Hotel
                  1 East Chang An Avenue
                  Beijing 100738

During the conference, the management will be available to meet with analysts and portfolio managers. Interested parties and investors who wish to meet with China-Biotics management may contact vivian.chen@ccgir.com or call (310) 926-8038. Participation in the SIG 3rd Annual Beijing Management Summit is by invitation only.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

    For more information, please contact:

     Lewis Fan, CFO
     China-Biotics, Inc.
     Email: lewisfan@chn-biotics.com
     Web:  http://www.chn-biotics.com

    CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results
2. China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
3. China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations
4. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results
5. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
6. China-Biotics, Inc. to Join Russell 3000 Index
7. China-Biotics, Inc. to Attend Digestive Disease Week 2009
8. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
9. China-Biotics, Inc. Supplies Probiotics as Additive for Poultry Feed
10. China-Biotics, Inc. Appoints New Chief Financial Officer
11. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017  Asterias Biotherapeutics, Inc. ... field of regenerative medicine, today announced positive efficacy ... clinical trial that showed additional motor function improvement ... million AST-OPC1 cells in AIS-A patients with complete ... of upper extremity motor function is critically important ...
(Date:1/24/2017)... Switerland (PRWEB) , ... January 24, 2017 , ... ... first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of histidine ... which are available in a range of concentrations from six different malaria strains, ...
(Date:1/24/2017)... , ... January 23, 2017 , ... Oklahoma City based ... newest client for the firm’s PERFEQTA software and legacy product QC Manager 2.0. ... the dynamic team at CJBC and thrilled that they have decided to implement PERFEQTA ...
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... into an underwriting agreement with Rodman & Renshaw, a ... as sole book running manager and representative of several underwriters, ... a firm commitment basis a minimum of 2,105,264 shares ... to purchase a minimum of 1,052,632 shares of common ...
Breaking Biology Technology:
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):